Cyclerion Therapeutics, Inc. 8-K

What Happened
Cyclerion Therapeutics, Inc. (CYCN) announced on February 17, 2026 that it issued a press release providing an update on the development of its lead product candidate, CYC-126, and the formation of a clinical advisory board to support the program. The disclosure was filed as a Regulation FD disclosure on Form 8-K and the full press release is attached as Exhibit 99.1.

Key Details

• Press release dated February 17, 2026, was furnished under Item 7.01 (Regulation FD Disclosure).
• The announcement covers development progress for CYC-126, Cyclerion’s lead clinical candidate.
• Cyclerion has formed a clinical advisory board to advise on the CYC-126 program.
• The press release is included as Exhibit 99.1 to the Form 8-K (and the filing includes the cover page interactive data file as Inline XBRL).

Why It Matters
This filing provides investors with an official, public update on Cyclerion’s lead drug candidate and the company’s steps to engage external clinical expertise. Formation of a clinical advisory board can indicate management is organizing clinical strategy and preparing for upcoming development milestones; however, the 8-K itself does not disclose trial results, timelines, or financial impacts. Investors should read the attached press release for full details and watch for subsequent updates on clinical plans, regulatory steps, or data releases.